Cancer Discovery Publishes Preclinical And Initial Clinical Data For MRTX1719 To Treat MTAP-Deleted Cancers through Novel Approach To MTA-Cooperative PRMT5 Inhibition
Portfolio Pulse from Happy Mohamed
Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced that Cancer Discovery published preclinical and initial clinical data from a Phase 1/2 clinical trial of MRTX1719, a PRMT5 / MTA-cooperative inhibitor evaluated in MTAP deleted cancers. The results demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker. In preclinical studies, MRTX1719 showed marked anti-tumor activity across various solid tumor models. The drug was well-tolerated with no dose limiting toxicities observed.
August 09, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics' MRTX1719 shows promise in treating MTAP deleted cancers, potentially opening a new market for the company. The drug's positive preclinical and initial clinical results could boost investor confidence.
The positive results from the Phase 1/2 clinical trial of MRTX1719 could potentially open a new market for Mirati Therapeutics, as the drug targets a specific biomarker present in ~10% of cancer patients. This could lead to increased investor confidence in the company's ability to develop effective cancer treatments, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100